Dr David Brown has 40 years experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with 4 of the top 10 pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche. Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for 8 years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these drugs have sales over $30 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.
In more recent years he has focused on start-up biotechnology companies due to his strong interest in entrepreneurialism. He coaches CEOs and entrepreneurs at Cambridge University Business School and he is an Angel Investor. He was President and Chief Executive of Cellzome AG, a biotechnology company with headquarters in Heidelberg, Germany (acquired by GSK). He then co-founded Crescendo Biologics Ltd, and he currently chairs several biotechnology companies including Healx Ltd, ProFactor Pharma Ltd, and Amura Ltd.